We recently compiled a list of the 10 Best Genomics Stocks To Buy Right Now. In this article, we are going to take a look at ...

Phase 3 trial of Biogen and UCB's dapirolizumab pegol shows significant improvement in lupus disease activity. Read more here ...

After the unexpected success of their PHOENYCS GO study for dapirolizumab pegol in lupus earlier this fall, Biogen and UCB ...

Biogen (NASDAQ:BIIB – Get Free Report) was downgraded by equities research analysts at Needham & Company LLC from a “buy” ...

A handful of billion-dollar deals in the rare disease space highlights the uptick in Big Pharma’s investment, but it’s still ...

DelveInsight's 'Systemic Lupus Erythematosus Pipeline Insight 2024' report provides comprehensive global coverage of pipeline systemic lupus erythematosus therapies in various stages of clinical ...

The European Commission grants marketing authorization to 2 aflibercept biosimilars; Biosimilars Canada launches new campaign ...

In a report released today, Phil Nadeau from TD Cowen maintained a Buy rating on Rhythm Pharmaceuticals (RYTM – Research Report), with a price ...

Medline today announced that it has expanded its medical surgical prime vendor agreement with Northern California-based ...

CareMessage, the largest patient activation platform in the United States for underserved populations, today announced the launch of their AI Assistant, adding ethical AI tools to their market-leading ...

But since the start of last year, two Alzheimer's treatments have been approved in the United States: Biogen's lecanemab and Eli Lilly's donanemab. They work by targeting the build-up of two proteins ...

In this article, we are going to take a look at where Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) stands against the other ... adding five more stocks to the roster including Amgen (NASDAQ:AMGN), ...